CureVac (CVAC) Stock Price, News & Analysis

Company Overview

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Key Stats

• Today's Range: $2.83 to $2.98
• 50-Day Range: $2.89 to $4.18
• 52-Week Range: $2.22 to $5.28
• Volume: 973,221 shs
• Average Volume: 816,893 shs
• Market Capitalization: $647.01 million
• P/E Ratio: 5.25
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Hold

CureVac Stock Analysis - MarketRank™

CureVac scored higher than 66% of companies evaluated by MarketBeat, and ranked 317th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

CureVac has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

CureVac has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for CureVac are expected to decrease in the coming year, from $0.72 to ($0.39) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CureVac is 5.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.48.

Price to Earnings Ratio vs. Sector

The P/E ratio of CureVac is 5.25, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.74.

Price to Book Value per Share Ratio

CureVac has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.18% of the float of CureVac has been sold short.

Short Interest Ratio / Days to Cover

CureVac has a short interest ratio ("days to cover") of 4.8.

Change versus previous month

Short interest in CureVac has recently increased by 4.55%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CureVac does not currently pay a dividend.

Dividend Growth

CureVac does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -2.34

Percentage of Shares Shorted

4.18% of the float of CureVac has been sold short.

Short Interest Ratio / Days to Cover

CureVac has a short interest ratio ("days to cover") of 4.8.

Change versus previous month

Short interest in CureVac has recently increased by 4.55%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 6 people have searched for CVAC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CureVac insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.15% of the stock of CureVac is held by insiders.

Percentage Held by Institutions

Only 17.26% of the stock of CureVac is held by institutions.

CVAC Stock Analysis - Frequently Asked Questions

How have CVAC shares performed this year?

CureVac's stock was trading at $3.41 at the start of the year. Since then, CVAC stock has decreased by 15.2% and is now trading at $2.89.
View the best growth stocks for 2025 here.

How were CureVac's earnings last quarter?

CureVac (NASDAQ:CVAC) announced its quarterly earnings results on Sunday, November, 29th. The company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($54.37) by $54.13. CureVac had a net margin of 20.72% and a trailing twelve-month return on equity of 21.98%.

When did CureVac IPO?

CureVac (CVAC) raised $200 million in an IPO on Friday, August 14th 2020. The company issued 13,300,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse served as the underwriters for the IPO and Berenberg and Kempen were co-managers.

Who are CureVac's major shareholders?

Top institutional investors of CureVac include Millennium Management LLC (0.74%), Alyeska Investment Group L.P. (0.22%), Point72 Asset Management L.P. (0.20%) and DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main (0.11%).

How do I buy shares of CureVac?

Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CureVac own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CureVac investors own include NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA), NIO (NIO), Advanced Micro Devices (AMD), Meta Platforms (META) and Moderna (MRNA).

Company Calendar

• Last Earnings: 11/29/2020
• Today: 3/23/2025
• Next Earnings (Estimated): 4/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CVAC
• CIK: 1809122
• Web: www.curevac.com
• Phone: 49-70-71988-30
• Fax: 49-7071-9883
• Employees: 880
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $16.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +246.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.55
• Trailing P/E Ratio: 5.25
• Forward P/E Ratio: 4.01
• P/E Growth: N/A
• Net Income: $-281,580,000.00
• Net Margins: 20.72%
• Pretax Margin: 27.11%
• Return on Equity: 21.98%
• Return on Assets: 15.72%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 6.20
• Quick Ratio: 6.19

Sales & Book Value

• Annual Sales: $543.28 million
• Price / Sales: 1.19
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.50 per share
• Price / Book: 1.16

Miscellaneous

• Outstanding Shares: 223,880,000
• Free Float: 219,067,000
• Market Cap: $647.01 million
• Optionable: Optionable
• Beta: 2.53